Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of EGF816 (Nazartinib) in EGFR-mutant Solid Malignancies
jRCT2080222568Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2014
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of nazartinib in EGFR-mutated non-small cell lung cancer, sponsored by Novartis. Started Jul 2014; status: completed.
02
Drugs
nazartinib
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2080222568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222568.